• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Intuitive Surgical slides hard but beats The Street in Q3

Intuitive Surgical slides hard but beats The Street in Q3

October 17, 2013 By Arezu Sarvestani

Intuitive Surgical beats The Street, even as sales slide in Q3

California medical device maker Intuitive Surgical (NSDQ:ISRG) managed to tromp analysts’ expectations during its 3rd quarter, even as the company wrangles with the public relations nightmare growing out of a series of patient injury lawsuits.

Intuitive beat Wall Street’s expectations by a whopping 59¢ per diluted share, even as Q3 sales dropped 7.2% and profits dropped 14.5%.

The device maker reported earnings of $156 million, or $3.99 per share, on sales of $499 million for the 3 months ended September 30. That compared with earnings of $183.3 million, or $4.46 per share, on sales of $537.8 million during the same period last year.

Analysts had estimated that Intuitive would post earnings of $3.40 for the quarter, nearly 15% lower than the actual turnout.

Intuitive Surgical has been a roller coaster in recent months, facing harsh criticism from analysts and media while facing a raft of patient injury lawsuits accusing the company of pushing surgeons on the company’s flagship da Vinci robot-assisted surgical system before they were properly trained.

The company still has some friends on Wall Street, with analysts at William Blair this month defending the company as a solid long-term investment, but others have been less kind.

Intuitive Surgical’s share price lost 25.3% this year as the company struggled with a series of studies finding robotic surgery equally safe and effective but more expensive than laparoscopy. Investors, who sent ISRG shares to an all-time high of $585.82 apiece in April 2012, have carved some 36.6% from the stock since then.

The device maker has also been publicly battling analysts at Citron Group, which has this year published a series of harsh criticisms of Intuitive’s track record at the FDA. Citron in January 2013 published all of the FDA’s da Vinci adverse event filings, comprising 12 years’ worth of reporting. Earlier this month Citron released another report, accusing Intuitive Surgical of ignoring a surge of new incidents that have cropped up in the FDA’s system.

Intuitive’s latest earnings report did little to stir investors today, with ISRG shares down 0.6% to $399.13 as of about 4:15 p.m.

Filed Under: News Well, Surgical Robotics, Wall Street Beat Tagged With: 2013, Intuitive Surgical, Q3

More recent news

  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland
  • Brain Navi wins FDA nod for neurosurgical robot
  • Adona Medical completes enrollment in first-in-human interatrial shunt trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy